Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.20.1
Commitments and Contingencies (Details Narrative)
3 Months Ended
Feb. 18, 2020
USD ($)
Sep. 12, 2018
USD ($)
Aug. 20, 2018
USD ($)
Apr. 05, 2018
USD ($)
Apr. 05, 2018
EUR (€)
Apr. 02, 2018
Mar. 22, 2018
USD ($)
Sep. 14, 2015
USD ($)
Dec. 24, 2013
USD ($)
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2019
USD ($)
Research and development costs                   $ 94,673 $ 48,314  
NDA Consulting Corp [Member]                        
Agreement term                 1 year      
Consulting and advisory fee                 $ 4,000 4,000 4,000  
Clinical Trial Research Agreement [Member]                        
Research and development costs                   58,760    
Clinical Trial Research Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]                        
Company paid amount for clinicl trial                   13,667 0  
Collaboration Agreement [Member]                        
Research and development costs                   87,471    
Collaboration Agreement [Member] | BioPharmaWorks LLC [Member]                        
Research and development costs                   30,000 10,000  
Consulting and advisory fee               $ 10,000        
Collaboration Agreement [Member] | Grupo Espanol de Investigacion en Sarcomas [Member]                        
Advance amount related to milestone payment $ 43,411                      
Clinical Trial Agreement [Member]                        
Aggregate commitments expected                   $ 4,806,000    
Aggregate commitments expected, description                   The Company's aggregate commitments pursuant to these clinical trial agreements, less amounts previously paid to date under these agreements, totaled approximately $4,806,000 as of March 31, 2020, which are expected to be incurred over the next five years through March 31, 2025.\    
Work Order Agreement [Member]                        
Research and development costs                   $ 69,178    
Work Order Agreement [Member] | Theradex Systems, Inc [Member]                        
Research and development costs   $ 954,000               5,686 32,964  
Payment expected dividend for pass-through costs, description   The clinical trial is expected to be completed over a period of two years, with final analysis and reporting expected within three years. Costs under this work order agreement are estimated to be approximately $954,000, with such payments expected to be divided approximately 94% to Theradex for services and approximately 6% for payments for pass-through costs.                    
Material Transfer Agreement [Member] | INSERM [Member] | Development Milestones [Member] | Maximum [Member]                        
Milestone payments             $ 1,750,000          
Material Transfer Agreement [Member] | INSERM [Member] | Commercial Milestones [Member] | Maximum [Member]                        
Milestone payments             $ 6,500,000          
Consulting Agreement with Liberi Life Consultancy BV [Member]                        
Agreement term           2 years            
Payment of a fixed, one-time retainer       $ 18,348                
Net payments of sales of products or licensing activities, percentage       2.50% 2.50%              
Consulting Agreement with Liberi Life Consultancy BV [Member] | EURO [Member]                        
Payment of a fixed, one-time retainer | €         € 15,000              
Consulting Agreement [Member]                        
Amortizing the retainer payment                   2,294 2,294  
Unamortized balance of the retainer payment                       $ 9,174
Exclusive License Agreement [Member]                        
Amount charges to operations                   $ 6,165 $ 15,274  
Royalties description                   The Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $50,000 in the first four years after sales commence, and $100,000 in year five and each year thereafter, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in the License Agreement.    
Exclusive License Agreement [Member] | First Four Years [Member]                        
Minimum payments for royalties                   $ 50,000    
Exclusive License Agreement [Member] | Five Years and Thereafter [Member]                        
Minimum payments for royalties                   $ 100,000    
Exclusive License Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]                        
Non-refundable license issue fee     $ 25,000                  
Clinical trial analysis expected term     2 years                  
Clinical trial final analysis expected term     3 years                  
Annual license maintenance fee     $ 25,000                  
Payments on non-refundable milestone     $ 1,897,000                  
Percentage of milestone     40.00%